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INTRODUCTION
The majority of patients with non-small cell lung cancer (NSCLC)
with epidermal growth factor receptor (EGFR) activating muta-
tions, such as exon 19 deletion and L858R point mutation, show
marked responses to EGFR tyrosine kinase inhibitors (EGFR-
TKIs), such as gefitinib, erlotinib, and afatinib (1-4). However, 20-
30% of patients with EGFR -activating mutations show intrinsic
resistance to EGFR-TKIs. Molecular mechanisms of the intrinsic
resistance are not fully understood(5).
BIM, also called Bcl -2 - like protein 11, is a pro-apoptotic mole-
cule that belongs to the Bcl -2 family. BIM upregulation is essential
for the induction of apoptosis in lung cancer cells with EGFRmuta-
tions treated with first -generation EGFR-TKIs, and a low BIM pro-
tein level is associated with resistance to EGFR-TKIs (6, 7). Re-
cently, an East Asian-specific 2,903 bp deletion polymorphism in
the BIM gene was discovered, whose incidence was around 13%
and 0.5% for heterozygous and homozygous carriers, respectively
(8). Importantly, the BIM deletion polymorphism results in the
preferential splicing of exon 3 over the BH3-encoding exon 4 in the
BIM pre-mRNA, and leads to the production of inactive BIM iso-
forms lacking the BH3 domain. This in turn reduces expression of
pro-apoptotic BIM protein isoforms in EGFR -mutant lung cancer
cell lines following TKI exposure and is sufficient to confer TKI
resistance (8). Since its initial discovery, several meta-analyses
have reported an association between BIM deletion polymorphism
and shorter progression-free survival (PFS) of patients with NSCLC
harboring EGFR mutations, who received gefitinib or erlotinib
treatment(9-13).
Vorinostat (suberoylanilide hydroxamicacid [SAHA]), has been
approved in 20 countries to date including Japan for cutaneous T-
cell lymphoma as monotherapy, is a small -molecule inhibitor of
histone deacetylase (HDAC) that induces cell differentiation, cell
cycle arrest, and apoptosis in several types of tumor cell lines (14).
We previously reported that the combined use of vorinostat and
gefitinib was able to preferentially upregulate the expression of pro-
apoptotic BIM isoforms in EGFR -mutant NSCLC cell lines with the
BIM deletion polymorphism, and overcome EGFR-TKI resistance
in vitro and in vivo (15). Two clinical trials, a phase I/II study
combining gefitinib and vorinostat in patients with advanced NSCLC
regardless of presence/absence of EGFR mutation in Korea (16)
and a phase I/II study combining erlotinib and vorinostat with ad-
vanced EGFR -mutant NSCLC patients after EGFR-TKI progres-
sion in Spain (17) have been performed. However, the combination
treatment did not show significant efficacy in these patient popula-
tion and novel biomarker is warranted. Therefore, based on our
preclinical findings, we designed the present phaseI study named
VICTORY-J “Vorinostat - Iressa Combined Therapy on Resistance
by BIM Polymorphysim in EGFRMutant Lung Cancer” to evaluate
the safety of combined therapy with vorinostat and gefitinib, and to
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determine the maximum tolerated dose (MTD) of vorinostat com-
bined with a fixed dose of gefitinib for Japanese patients with EGFR-
mutant NSCLC with a BIM deletion polymorphism.
METHODS AND DESIGN
Purpose
The primary objective is to determine the MTD of vorinostat
combined with a fixed dose of gefitinib for patients with EGFR -
mutant NSCLC with a BIM deletion polymorphism. Thesecondary
objective is to evaluate the safety and efficacy of the combined
therapy with vorinostat and gefitinib in the early -phase trial set-
ting.
Study design
This study is an open- label, multi - institutional phase I dose-
escalation study of participating institutions, include 5 specialized
centers in Japan as of November 2016. Participating institutions are
listed in Appendix 1.
Three to six patients will be enrolled at each dose level of vori-
nostat. With a fixed dose of gefitinib, dose escalation of vorinostat
following a conventional 3+3 design using an escalation scheme
will be used (Figure 1). Initially, 3 patients are enrolled to level 1. If
one or two patients experience DLT, 3 additional patients are en-
rolled to the level. If 3 of 6 patients experience DLT, the previous
level is declared the MTD. If 2 or less of 6 patients experience DLT,
dose escalation is permitted to continue. After the termination of
protocol treatment, any treatment is allowed.
Ethical considerations and registration
This study was conducted in accordance with the International
Committee for Harmonization Good Clinical Practice (ICH-GCP)
guideline and the Declaration of Helsinki. The study protocol was
approved by the institutional review boards of all participating
institutions. Informed consent will be provided for all patients
before registration. This study was registered with ClinicalTrials.
gov (NCT02151721) and UMIN Clinical Trials Registry (UMIN
000015193).
Endpoint
The primary endpoint is MTD, which is defined as the highest
dose level at which 2 or less of 6 patients experience a dose- limiting
toxicity (DLT). Toxicities will be graded according to the National
Cancer Institute Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0. DLT is defined as follows ; grade1 intesti-
nal lung disease ; grade4 neutropenia lasting 5 days or more ;
febrile neutropenia ; grade3 thrombopenia requiring platelet
transfusion ; grade4thrombopenia ; any grade uncontrollable
skin toxicity ; grade3 nonhematological toxicity. DLT will be
evaluated during the first two cycles(14 days per cycle) of therapy.
The secondary endpoints are pharmacokinetics and pharma-
codynamics of vorinostat and gefitinib, progression-free survival
(PFS), overall survival (OS), response rate (RR), duration of re-
sponse and complete response, disease control rate (DCR), and
incidence of adverse events defined by Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0.
Eligibility criteria
Inclusion criteria
Prior to enrollment in the study, patients must fulfill all of the
following criteria : histologically or cytologically diagnosed NSCLC
(excluding squamous cell carcinoma) ; NSCLC of clinicopathologic
stage IIIB or IV for which radical radiation therapy is impractical or
there is a recurrence after surgery ; EGFRmutations (deletion of
exon 19 and L858R mutation of exon 21) for which the clinical
benefits of an EGFR-TKI (gefitinib or erlotinib) are recognized by
testing methods that are listed by the national health insurance ;
having a history of treatment with an EGFR-TKI (gefitinib or er-
lotinib) and a history of pathologic deterioration during treatment ;
having a history of treatment with cytotoxic anticancer agents (not
including pre- or postoperative chemotherapy in the previous 1 or
Figure 1. Study design.
Dashed arrow ; if no DLTs are observed in all of 3 patients at lower dose level, additional 3 patients are recruited. DLTs, dose- limiting toxicities. MTD,
maximum tolerated dose.
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more years from the day of final administration) ; confirmed BIM
polymorphism by the PCR fragment analytical method and the
sequence method at the central laboratory ; having a lesion
measureable according to the RECIST guidelines version 1.1 ;
confirmed progression of pathology at the site of irradiation after
irradiation in a patient who only has an irradiated lesion ; age 20
years and older ; Eastern Cooperative Oncology Group (ECOG)
Performance Status (PS) 0 or 1 at the time of consent acquisition ;
an estimated life expectancy of 12 or more weeks ; a patient whose
acute toxicities in response to prior treatments have recovered to
the baseline level in the most recent prior treatment, excepting
adverse events considered not to be a safety concern at the discre-
tion of the investigator ; acquisition of written informed consent to
participate in the present study ; and adequate hematological, liver,
renal and respiratory function within 14 days before entry as
shown below.
i) Neutrophil count of1,500/μL.
ii) Platelet count of100,000/μL.
iii) Total bilirubin level of1.5- fold of the upper limit of refer-
ence value at each institution.
iv) Creatinine level of1.5mg/dL.
v) PaO2 of70 Torr or SpO2 of94%.
Exclusion criteria
Patients will be excluded for any of the following reasons : they
received the final administration of a cytotoxic anticancer agent
within the past 4 weeks, they received the final administration of an
EGFR-TKI within the past 7 days, or they received surgery or
radiotherapy for a primary tumor or mediastinum within the past 6
months ; radiotherapy considered necessary ; having an intersti-
tial lung disease or history thereof, radiation pneumonitis treated
with corticosteroids or having a history thereof, a large volume of or
uncontrollable pleural effusion, ascites, or pericardial effusion, or a
serious infection and other serious complications ; detection of
known resistance mutations of the EGFR, e.g., T790M ; suffering
from a severe or poorly controlled systemic disease ; having an
active or poorly controlled or symptomatic metastasis to the central
nervous system, or an active double cancer ; verified hepatitis B
virus antigen or C virus antibody positivity.
Patient registration and randomization
The investigators will send a patient registration form to the
independent data center at Center for Advanced Medicine and
Clinical Research, Nagoya University Hospital. Patient registration
began on May 2014 and is set to continue until March 2017.
Treatment
Vorinostat (level 1 : 200 mg, level 2 : 300 mg, level 3 : 400 mg)is
administered orally once daily on days 1-7, and gefitinib 250 mg
orally once daily on days 1-14.
Follow-up
After completion of scheduled treatment, the patients will be
followed up until death over a period of at least 1 year. All pa-
tients are required to undergo chest and abdominal computed
tomography at 6-month intervals during the first 24 weeks and at
12-week intervals after this period. Brain magnetic resonance
imaging or computed tomography is required following the same
schedule but only for patients with brain metastasis at the time of
enrollment (Table 1).
Sample size determination
Sample size was determined based on a conventional 3+3 phase I
design for oncology drugs.
Statistical analysis
The population analyzed for the primary endpoint included the
enrolled patientswith complete safety data onDLT during the first
twocycles.
RESULTS AND DISCUSSION
This is the first study to investigate the safety and preliminary
efficacy of combined therapy with vorinostat and gefitinib for
NSCLC patients with both EGFR mutations and a BIM deletion
polymorphism. The double selection for EGFR mutations and a
BIM deletion polymorphism is feasible. EGFR mutation analysis is
covered by health insurance in Japan and is widely used in clinical
practice for patients with NSCLC. The BIM deletion polymor-
phisms can be analyzed using DNA purified from mononuclear
cells in 5 ml of peripheral blood within 14 days. We conducted a
study, named PEOPLE-J, to screen for BIM deletion-positive indi-
viduals in the population of EGFR -mutant NSCLC patients. We
identified more than 74 BIM deletion polymorphism-positive indi-
viduals among 500 EGFR -mutant NSCLC patients by 25th Novem-
ber 2016.
After determining the recommended dose of vorinostat combined
Table1. Schedule of study assessments and evaluations.
Screening
Treatment Cycle Post -treatment
1 2 3 4 andbeyond End of
Treatment
Safety
Follow -up
day 1 day 2 day 3 day 4 day 8 day 1 day 8 day 1 day 8 day 1 30 days post -discontinued
Informed Consent
Inclusion/Exclusion Criteria
Blood test
Chest X -P
ECG
Tumor Imaging 6 -week (7 days) intervals during the first 24 weeks, and after this period, 12 -week (14 days) intervals
Blood for Pharmacokinetics
Blood for Pharmacodynamics
Review Adverse Events
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with gefitinib in Japanese EGFR -mutant NSCLC patients with BIM
deletion polymorphism in thisinvestigator- initiated trial, we would
like to conduct phase II study in cooperation with pharmaceutical
companies. If successful, this combined treatment with vorinostat
and gefitinib may lead to substantial and important changes in the
management of patients with EGFR mutant NSCLC with a BIM
deletion polymorphism.
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